Revenue Drain Among Challenges For ACNU OTC Marketers From Simultaneous Rx Availability

Final rule’s requirement that ACNU formulations also remain available as Rx generics could limit revenues for marketers of the nonprescription drugs while approvals of ACNU applications from studies with participants having drugs delivered to their homes may require marketers to limit distribution to direct-to-consumer without clearance for sales in retail stores.

(Source: Shutterstock/Citeline)

The “new paradigm” for OTC switches opening in the US with the Food and Drug Administration’s “additional conditions for nonprescription use” final rule published recently also brings new challenges for drug firms, the agency and the marketplace.

The rule’s requirement that formulations approved as additional conditions (ACNU) switches also remain available as Rx generics could limit the revenues for marketers of the nonprescription drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rx-to-OTC Switch

More from HBW Insight

Self-Care Must Be Central To NHS Reform, Says UK Industry And Pharmacy Alliance

 
• By 

Ahead of a soon to be released 10-Year Health Plan for the English NHS, an alliance including PAGB calls for self-care to be “clearly recognised and supported through concrete policies that reflect its vital role in achieving the plan’s goals.”

OTC Marketing Awards 2025 Open For Entries

 
• By 

Find out how to enter the OTC Marketing Awards before the 1 September entry deadline.

Haleon Study: Boosting Health Literacy Could Save Major Economies Over $300bn Per Year

 
• By 

By addressing disparities in health literacy, particularly in the areas of oral care, bone health, nutrition and air pollution, the consumer health industry can “save lives and billions in healthcare costs, boosting productivity and increasing GDP,” says a new report from Haleon and Economist Impact.